%0 Journal Article
%A Moreno, Victor
%A Roda, Desamparados
%A Pikiel, Joanna
%A Trigo, Jose
%A Bosch-Barrera, Joaquim
%A Drew, Yvette
%A Kristeleit, Rebecca
%A Hiret, Sandrine
%A Bajor, David L
%A Cruz, Patricia
%A Beck, J Thaddeus
%A Ghosh, Srimoyee
%A Dabrowski, Christine
%A Antony, Grace
%A Duan, Tao
%A Veneris, Jennifer
%A Zografos, Eleftherios
%A Subramanian, Janakiraman
%T Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
%D 2022
%U http://hdl.handle.net/10668/22104
%X Dostarlimab is an anti-programmed cell death protein-1 antibody being evaluated in recurrent/advanced solid tumors, including non-small cell lung cancer (NSCLC), in the ongoing Phase I, multi-center, open-label, 2-part (dose escalation and cohort expansion) GARNET study (NCT02715284). Here, we report an interim analysis of patients with recurrent/advanced NSCLC who progressed following platinum-based chemotherapy. Patients received dostarlimab (500 mg IV every 3 weeks [Q3W] for Cycles 1-4, then 1000 mg Q6W) until disease progression or unacceptable toxicity for > 2 years. The primary endpoints were immune-related objective response rate (irORR) per investigator-assessed irRECIST and safety. As of 8, July 2019, 67 patients with recurrent/advanced NSCLC were enrolled and treated with dostarlimab; the majority had programmed death ligand 1 (PD-L1) tumor proportion score (TPS)  Dostarlimab demonstrated promising antitumor activity in advanced/recurrent NSCLC that progressed following platinum-based chemotherapy, including across all PD-L1 subgroups, and has an acceptable safety profile.
%K Cancer immunity
%K Immune checkpoint inhibitors
%K Lung neoplasms
%K PD-1
%K Treatment outcome
%~